ValueGen.AI automates the most time-consuming HEOR and market access tasks — evidence synthesis, economic modeling, HTA intelligence, and payer strategy — with full traceability and domain-specific reliability scoring.
A generative AI platform that automates evidence synthesis, economic modeling, payer strategy, and HTA intelligence — with full traceability and domain-specific reliability scoring.
Submission-ready outputs across HEOR and market access — in formats your stakeholders already use. Generated in days, not months.
Markov or decision-tree CEA with PSA, tornado diagrams, ICER outputs, and country-specific threshold analysis.
Payer-level BIM with market uptake, patient share, cost offsets, and scenario toggles.
Browser-based model with sliders and real-time scenario exploration — shareable with payers and HTA bodies.
Comprehensive disease-area landscape generated in 48 hours: HTA history, guidelines, and published evidence across 7 markets.
Structured report ranking evidence gaps by strategic priority with recommendations for clinical study design.
Concise clinical evidence narrative for FDA, EMA, or HTA dossier submissions with source citations.
Live dashboard tracking HTA decisions, payer positions, and reimbursement status across NICE, G-BA, HAS, ICER, CADTH, AIFA, AEM.
Structured dossier narrative — clinical summary, PICOTS, economic model narrative, and appendices aligned to each HTA body template.
Q&A document with anticipated payer objections and structured counterarguments on efficacy, durability, and pricing.
Multi-country reimbursement summary covering coverage, formulary placement, access restrictions, and price benchmarking.
1–2 page briefing synthesizing clinical evidence, budget impact, and access context for field teams ahead of payer meetings.
Localized model and narrative adapted to country-specific epidemiology, unit costs, comparators, and HTA methodology.
Domain depth, traceability, and enterprise-grade reliability — engineered for the regulated workflows of HEOR and market access teams.
Trained and optimized for HEOR and market access — not a general LLM wrapper. Natively understands HEOR methodologies, NICE appraisal logic, and CEA model structures.
Every output includes source citations and evidence grounding. Outputs are auditable — essential for regulatory submissions and payer negotiations.
A proprietary framework flags outputs by evidence quality, novelty risk, and domain complexity — telling users exactly when to trust versus verify output.
Natively processes HTA reports in French, German, Italian, Spanish, and English — summarizing in English. Covers NICE, G-BA, HAS, ICER, CADTH, AIFA, AEM, and more.
Landscape assessments in 48 hours versus months. Objection handlers in minutes. Frees senior experts for high-value strategic work that requires human judgment.
SSO/Auth0, role-based access control, TLS 1.2 encryption, data encrypted at rest. Client data is never used for model retraining or secondary purposes.
From cost-effectiveness analysis and budget impact modeling to evidence synthesis and HTA body-specific analyses — ValueGen.AI accelerates every stage of the evidence lifecycle.
AI-driven insights for reimbursement strategy, HTA navigation, payer communication, and competitive positioning — across NICE, G-BA, HAS, ICER, CADTH, AIFA, and AEM.
Partnering with global leaders across pharma, biotech, and health technology assessment.
ValueGen.AI replaces months of manual effort with AI-powered workflows that HEOR and market access professionals can trust and act on immediately.
Get Started